《瑞信窩輪》比亞迪急挫港交所急跌,留意比迪牛57477、港交牛54227
比亞迪股份(1211)周五公布季績前,突急挫近7%至170元邊緣,回落至逾7個月低位。向上或以重上10天線約192元為短期目標,支持或參考160元水平。看好可留意比迪購26125,行使價230.20元,23年3月到期。或比迪牛57477,收回價151.00元,行使價147.00元,22年12月到期。相反看淡可留意比迪沽24513,行使價167.78元,23年5月到期。或比迪熊54916,收回價200.00元,行使價204.00元,23年10月到期。
同樣周五公布季績的新能源電池相關股贛鋒鋰業(1772),曾跌逾3%至54元以下。看好可留意贛鋒購25170,行使價64.33元,23年1月到期。
港交所(0388)周五先升後回,高位突破230元後遇獲利盤,曾倒跌逾2%至220元以下。向上觀望收復10天線約243元的機會,220元水平尚待重建支持。看好可留意港交購26706,行使價279.99元,23年3月到期。或港交牛54227,收回價201.88元,行使價199.88元,23年10月到期。相反看淡可留意港交沽27064,行使價209.80元,23年9月到期。或港交熊55824,收回價230.00元,行使價233.00元,23年9月到期。
匯豐(0005)走勢相對平穩,保持在40元以上整固。向上有待上試42元水平,支持或參考月內低見的38.5元水平。看好可留意匯豐購26015,行使價48.53元,23年3月到期。或匯豐牛69145,收回價38.08元,行使價37.08元,22年12月到期。相反看淡可留意匯豐沽26184,行使價33.95元,23年3月到期。或匯豐熊51295,收回價43.88元,行使價44.88元,23年3月到期。
藥明生物(2269)最多漲逾8%,高見43元,上方10天線約44.1元或具阻力。看好可留意藥明購25224,行使價50.93元,23年4月到期。或藥明牛59616,收回價35.88元,行使價34.38元,22年12月到期。相反看淡可留意藥明熊54224,收回價55.00元,行使價56.50元,23年11月到期。
以上產品資料來源: 彭博資訊及瑞信網站cswarrants.com
(本結構性產品並無抵押品)
《瑞信香港認股證及牛熊證銷售主管何啟聰》
免責聲明:筆者為瑞士信貸(香港)有限公司的代表,為證監會持牌人,並無持有相關上市公司的任何財務權益。本文內容僅供參考,並不構成要約、建議或促使任何人士提呈買賣或認購任何證券。結構性產品價格可急升或急跌,投資者或會蒙受全盤損失。本產品並無抵押品。如發行人無力償債或違約,投資者可能無法收回部份或全部應收款項。牛熊證備強制贖回機制而可能被提早終止,屆時(i)N類牛熊證投資者將不獲發任何金額;而(ii)R類牛熊證之剩餘價值可能為零。有關恆生指數,恆生中國企業指數或恆生科技指數的免責聲明,請參閱上市文件。過往表現並不反映將來表現。投資前,投資者應瞭解風險,並諮詢專業顧問及查閱有關上市文件。瑞信之聯屬公司Credit Suisse Securities (Hong Kong) Limited為結構性產品之流通量提供者,亦可能是唯一報價者。本文任何內容概不構成投資、法律、會計或稅務意見、並無聲明任何投資或策略適合或符合閣下的個別情況。結構性產品交投量並不是結構性產品表現的指標,投資者不應僅依賴交投量歷史高位數據以釐定結構性產品日後的表現。~
重要聲明:
以上資訊由第三方提供,AASTOCKS.com Limited對於任何包含於、經由、連結、下載或從任何與本網站有關服務所獲得之資訊、內容或廣告,不聲明或保證其內容之正確性或可靠性。對於您透過本網站上之廣告、資訊或要約而展示、購買或取得之任何產品、資訊資料,本公司亦不負品質保證之責任。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.